Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

The Role of Pharmacogenetics in Personalized Medicine: A Comprehensive Overview

Dinislam Khuzin [1], Ibieva Madina [2], Babugoeva Diana [3], Bolatova Mariam [4], Gadzhieva Valentina [5], Apikov Beslan [6], Khalimova Arina [7], Sergeeva Elena [8], Tsokieva Meddina [9]

1.Harbin Medical University, School of Clinical Medicine, Harbin, Heilongjiang, People's Republic of China
2.Saratov State Medical University named after V.I. Razumovsky, Russian Federation
3.Kuban State Medical University, Russian Federation
4.Kuban State Medical University, Russian Federation
5.Novosibirsk State Medical University, Russian Federation
6.North Caucasus State Academy, Russian Federation
7.Yaroslavl State Medical University, Russian Federation
8.Kursk State Medical University, Russian Federation
9.Russian National Research Medical University named after N.I. Pirogov, Russian Federation

(Received: 16 September 2024 Revised: 11 October 2024 Accepted: 24 December 2024)

KEYWORDS
interventions, pharmacogenetics, toxicity, cardiovascular,

ABSTRACT:
Personalized medicine is an evolving field that strives to optimize therapeutic interventions by tailoring medical treatments to the individual characteristics of each patient [1]. One of the key drivers of this paradigm shift is pharmacogenetics, a discipline that examines the influence of genetic variation on drug response [2]. By understanding how genetic factors determine drug efficacy and toxicity, pharmacogenetics promises to revolutionize medicine, particularly in the treatment of chronic diseases, cancers, psychiatric disorders, and cardiovascular conditions [3].

1. Introduction

Personalized medicine is an evolving field that strives to optimize therapeutic interventions by tailoring medical treatments to the individual characteristics of each patient [1]. One of the key drivers of this paradigm shift is pharmacogenetics, a discipline that examines the influence of genetic variation on drug response [2]. By understanding how genetic factors determine drug efficacy and toxicity, pharmacogenetics promises to revolutionize medicine, particularly in the treatment of chronic diseases, cancers, psychiatric disorders, and cardiovascular conditions [3].

The convergence of genomics, pharmacology, and bioinformatics has created unprecedented opportunities to customize healthcare at a molecular level [4]. Pharmacogenetics, specifically, empowers clinicians to select the most appropriate drug and dose based on an individual's genetic makeup, thereby enhancing therapeutic outcomes and minimizing adverse drug reactions (ADRs) [5]. This review aims to dissect the multifaceted role of pharmacogenetics in personalized medicine, highlighting its current clinical applications, ongoing challenges, and future potential [6]. Additionally, the review seeks to emphasize the importance of integrating pharmacogenetic knowledge into clinical guidelines to improve drug prescribing practices globally [7].

2. The Foundations of Pharmacogenetics

2.1 Defining Pharmacogenetics: Bridging Genetics and Pharmacology

Pharmacogenetics is the study of how genetic differences influence an individual's response to drugs [8]. This scientific discipline lies at the intersection of pharmacology—the study of drug action—and genetics, which governs the biochemical pathways and molecular targets involved in drug metabolism [9]. Genetic variations, often in the form of polymorphisms, can result in considerable inter-individual variability in drug efficacy, safety, and pharmacokinetics [10].

Pharmacogenetics examines various molecular mechanisms by which genetic variations affect drug absorption, distribution, metabolism, and excretion (ADME) [11]. These processes can differ significantly between individuals, leading to distinct therapeutic responses and the likelihood of adverse events [12]. A deeper understanding of these processes, combined with genetic screening, can optimize drug therapy,

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

transforming the practice of medicine from a "one-size-fits-all" approach to a highly personalized strategy [13].

2.2 The Pharmacokinetics of Drugs: The Role of Genetic Variability in Drug Metabolism

Pharmacokinetics, the study of drug movement through the body, is governed by genetic variability in enzymes responsible for drug metabolism [14]. Among the most studied genes in pharmacogenetics are those encoding drug-metabolizing enzymes, primarily members of the cytochrome P450 (CYP450) family [15]. These enzymes are responsible for the oxidative metabolism of a wide array of drugs, including antidepressants, antipsychotics, statins, and chemotherapy agents [16].

CYP450 enzymes exhibit substantial inter-individual variability due to genetic polymorphisms [17]. For example, the CYP2D6 enzyme is responsible for the metabolism of over 25% of all marketed drugs [18]. Genetic polymorphisms in the CYP2D6 gene result in classifications of individuals as poor, intermediate, extensive, or ultra-rapid metabolizers [19]. These variations directly influence the pharmacokinetics of drugs, determining whether a drug will be metabolized too slowly (leading to toxicity) or too quickly (leading to suboptimal therapeutic efficacy) [20]. Similarly, polymorphisms in CYP2C19, CYP2C9, and CYP3A4 can influence the metabolism of drugs ranging from anticoagulants (e.g., warfarin) to cancer chemotherapy agents (e.g., irinotecan) [21].

Genetic testing for polymorphisms in drug-metabolizing enzymes is a cornerstone of pharmacogenetic applications, as it allows clinicians to predict a patient's metabolic profile and adjust drug dosing accordingly [22].

2.3 Genetic Variability in Drug Transport and Targeting: The Influence of Genetic Polymorphisms

In addition to drug-metabolizing enzymes, genetic polymorphisms in drug transporters and molecular drug targets also play critical roles in determining drug response [23]. Drug transporters, such as the ATP-binding cassette (ABC) transporters and solute carrier (SLC) transporters, regulate the absorption and distribution of drugs across cellular membranes, influencing the bioavailability and therapeutic efficacy of drugs [24].

For instance, polymorphisms in the multidrug resistance protein 1 (MDR1, or ABCB1) gene, which encodes a drug transporter that pumps drugs out of cells, can significantly affect the pharmacokinetics of drugs such as digoxin and anticancer agents [25]. Variants of this gene can lead to altered drug distribution and response, affecting both the effectiveness and the potential toxicity of drugs [26].

Furthermore, genetic variations in drug targets, such as receptors and enzymes, can impact how drugs interact with their intended targets [27]. The epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) are two prominent examples in oncology, where specific genetic alterations determine whether patients will respond to targeted therapies like EGFR inhibitors (e.g., erlotinib) and HER2-targeted therapies (e.g., trastuzumab) [28].

2.4 Gene-Environment Interactions: The Complex Nature of Drug Response

While genetic factors are crucial in determining drug response, environmental factors, such as diet, lifestyle, and exposure to toxins, also play a substantial role [29]. The interaction between genetic predisposition and environmental factors—known as gene-environment interactions—can modify drug efficacy and toxicity [30]. For example, the consumption of grapefruit juice can inhibit the CYP3A4 enzyme, leading to altered pharmacokinetics of drugs metabolized by this enzyme, including statins and calcium channel blockers [31].

Personalized medicine aims to account for these complex interactions by incorporating not only genetic data but also environmental factors, thereby optimizing therapeutic strategies and minimizing the risk of ADRs [32]. In the future, integrated models that combine genetic, epigenetic, and environmental data will offer a more comprehensive understanding of how individuals respond to drugs [33].

3. Genetic Markers and Their Role in Treatment Decisions

3.1 Key Genetic Markers in Pharmacogenetics: Implications for Drug Therapy

The identification of genetic markers that predict drug response has catalyzed the field of pharmacogenetics [34]. These markers can guide clinicians in selecting the

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

right drug and dosing regimen for each patient [35]. Among the most important genetic markers influencing drug response are:

CYP450 Genes: As previously mentioned, genetic polymorphisms in CYP450 genes, particularly CYP2D6, CYP2C19, and CYP2C9, can drastically alter drug metabolism [36]. Pharmacogenetic testing of these genes can help guide the selection of antidepressants, antipsychotics, analgesics, and chemotherapy drugs [37].

VKORC1 and CYP2C9: The genes encoding vitamin K epoxide reductase (VKORC1) and cytochrome P450 2C9 (CYP2C9) are essential in the metabolism of warfarin, an anticoagulant with a narrow therapeutic index [38]. Variations in VKORC1 and CYP2C9 can result in significant differences in warfarin sensitivity, leading to a higher risk of bleeding or thrombosis [39]. Pharmacogenetic testing for these genes is now routinely recommended to individualize warfarin dosing [40].

TPMT: Genetic variants in the TPMT gene, which encodes thiopurine S-methyltransferase, affect the metabolism of thiopurine drugs such as azathioprine and mercaptopurine [41]. Patients with low TPMT activity are at higher risk for severe myelosuppression and require reduced doses of these drugs [42].

HER2 and EGFR Mutations: In cancer treatment, genetic mutations in the HER2 and EGFR genes can predict the effectiveness of targeted therapies [43]. HER2 overexpression in breast cancer, for example, makes tumors susceptible to HER2-targeted therapies like trastuzumab, while mutations in the EGFR gene predict responsiveness to EGFR inhibitors in lung cancer [44].

3.2 Pharmacogenetic Testing: Improving Drug Selection and Dosing

Pharmacogenetic testing provides a powerful tool to enhance clinical decision-making, enabling more precise drug selection and dosing [45]. The goal is to match patients with the drugs that are most likely to benefit them, while avoiding those that might cause harm [46]. The growing body of evidence supporting pharmacogenetic testing is reflected in its integration into clinical guidelines for a variety of drugs [47].

For instance, the Clinical Pharmacogenetics Implementation Consortium (CPIC) provides evidence-based guidelines for pharmacogenetic testing in drug therapy [48]. The CPIC has published recommendations on drugs like clopidogrel, warfarin, and carbamazepine, offering clear guidance on how to adjust dosing or select alternative therapies based on genetic test results [49]. The widespread adoption of such guidelines could substantially reduce the occurrence of ADRs and improve therapeutic outcomes [50].

3.3 Pharmacogenetic Biomarkers in Oncology: Revolutionizing Cancer Therapy

In oncology, pharmacogenetic biomarkers are being used to tailor chemotherapy regimens to individual patients, significantly improving treatment efficacy and reducing toxicity [51]. For example, the identification of HER2 amplification in breast cancer patients has led to the development of targeted therapies like trastuzumab (Herceptin), which significantly improves survival rates in HER2-positive breast cancer patients [52].

Similarly, mutations in the K-RAS gene can predict non-responsiveness to EGFR inhibitors in colorectal cancer patients, prompting clinicians to choose alternative therapies for these individuals [53]. As the field of cancer pharmacogenetics continues to expand, more genetic markers will be discovered that will help refine treatment strategies and improve patient outcomes [54].

4. Challenges in Implementing Pharmacogenetics in Clinical Practice

4.1 Lack of Awareness and Education Among Healthcare Providers

The integration of pharmacogenetics into clinical practice has been significantly impeded by a widespread lack of understanding and awareness among healthcare providers [55]. Despite its growing importance in personalized medicine, many clinicians, including physicians, pharmacists, and genetic counselors, lack the comprehensive training needed to fully interpret and apply pharmacogenetic data [56]. A study by Smith et al. (2020) revealed that only 30% of healthcare providers in the United States were familiar with the clinical applications of pharmacogenetic testing, and

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

even fewer had received formal education in this area [57].

As a result, many healthcare professionals continue to prescribe drugs based on empirical methods and population-level data rather than tailoring treatments to the individual genetic profiles of patients. This lack of expertise may result in suboptimal drug selection, ineffective treatments, and an increased risk of adverse drug reactions (ADRs) [58]. A gap in knowledge is also evident in the understanding of pharmacogenetic testing methodologies, with many clinicians unaware of the specific genetic markers associated with commonly prescribed drugs.

Addressing this issue requires urgent reforms in medical education, such as incorporating pharmacogenetics into undergraduate and postgraduate curricula across various healthcare professions. Additionally, expanding continuing medical education (CME) programs and integrating pharmacogenetic training into clinical residency programs can ensure that healthcare providers are equipped with the necessary knowledge to apply pharmacogenetic information effectively in practice [59].

4.2 Cost and Access to Pharmacogenetic Testing

While the price of genetic testing has decreased substantially over the last decade, the affordability and accessibility of pharmacogenetic tests remain a significant challenge, especially in low-income and rural areas [60]. In many settings, pharmacogenetic testing is considered an "add-on" service, often excluded from basic healthcare packages, and remains out of reach for many patients due to its cost, which can exceed several hundred dollars per test [61]. Moreover, insurance companies and government healthcare programs in several countries still lack clear reimbursement policies for pharmacogenetic tests, further hindering their widespread adoption [62].

In contrast, high-income countries such as the United States and some parts of Europe have begun to integrate pharmacogenetic testing into standard care pathways for specific drugs. However, the lack of consistency in reimbursement policies across different healthcare systems, along with varying levels of public awareness about the benefits of pharmacogenetic testing, continues to contribute to healthcare disparities [63].

For pharmacogenetic testing to reach its full potential, it must become a standard component of medical practice. There is a need for public health policy reforms that prioritize the inclusion of pharmacogenetics in universal healthcare coverage, making these tests affordable and accessible to all patients, regardless of their socioeconomic background [64].

4.3 Data Privacy and Ethical Concerns

As pharmacogenetics increasingly influences clinical decision-making, concerns about the privacy and ethical use of genetic data have emerged [65]. The collection, storage, and sharing of genetic data raise significant privacy issues, particularly when it comes to ensuring that sensitive genetic information is protected from misuse or discrimination [66]. Without proper safeguards, there is a risk that genetic data could be used for purposes beyond healthcare, such as employment or insurance discrimination, which could undermine patient trust and deter participation in pharmacogenetic testing [67].

Furthermore, the ethical implications of pharmacogenetic testing extend to issues of informed consent. Patients may not fully understand the potential implications of genetic testing, particularly regarding the privacy of their genetic information or the risk of identifying incidental genetic findings unrelated to the treatment at hand [68]. Ethical guidelines must be established to ensure that patients are fully informed of their rights, the scope of testing, and the potential consequences of genetic testing, particularly in populations that may not have access to adequate counseling [69].

To address these concerns, healthcare providers and policymakers must collaborate to establish robust data protection protocols, ensuring that genetic information is used ethically, with strict safeguards in place. Informed consent processes should be enhanced to provide patients with a clear understanding of the risks, benefits, and limitations of pharmacogenetic testing [70].

4.4 Limited Integration of Pharmacogenetics into Clinical Guidelines

While pharmacogenetic testing is recommended for certain medications, its integration into clinical guidelines remains inconsistent and limited to specific

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

therapeutic areas, such as oncology and psychiatry [71]. Even in cases where pharmacogenetic testing is recommended, the guidelines are often vague, leaving clinicians without clear instructions on how to incorporate genetic data into treatment decisions [72].

For example, while the use of genetic testing for warfarin dosing is widely accepted in clinical guidelines, the integration of pharmacogenetics into guidelines for commonly prescribed drugs like antidepressants, antihypertensives, and antidiabetics remains minimal [73]. This lack of clarity and standardization in clinical guidelines contributes to the underutilization of pharmacogenetic testing, even when it could significantly improve patient outcomes and reduce ADRs.

To overcome this, there needs to be a concerted effort to develop comprehensive, evidence-based pharmacogenetic guidelines for a broader range of medications. These guidelines should provide clear recommendations on when and how to use pharmacogenetic testing, ensuring that it becomes a routine part of clinical decision-making. Moreover, these guidelines should be regularly updated to reflect new research and technological advancements in pharmacogenetics [74].

5. Future Perspectives in Pharmacogenetics

5.1 Expanding the Scope of Pharmacogenetics in Drug Development

One of the most promising future applications of pharmacogenetics lies in its role in drug development [75]. Traditionally, drugs are developed for the "average" patient, without consideration for the genetic variability that exists within populations. This has often led to high rates of drug failure during clinical trials, as drugs that work for one genetic subgroup may be ineffective or harmful to others.

Pharmacogenetics can revolutionize drug development by guiding the design of drugs that are specifically tailored to the genetic profiles of patients. The use of pharmacogenetic data during the preclinical and clinical stages of drug development will allow pharmaceutical companies to select the most appropriate patient populations for trials, based on their genetic makeup. This targeted approach could significantly reduce the number of clinical trial failures, improve the efficiency of drug development, and shorten the time required to bring new drugs to market [76].

Moreover, pharmacogenetics can help identify new drug targets by uncovering the genetic pathways that influence disease progression. The identification of rare genetic mutations that contribute to drug resistance or toxicity could lead to the development of next-generation therapies that are more effective and have fewer side effects [77].

As pharmacogenetic research continues to evolve, it is likely that drug development will become increasingly personalized, with genetic data influencing every stage of the process, from initial discovery to final approval [78].

5.2 Integration with Artificial Intelligence and Big Data

The future of pharmacogenetics will also be shaped by the integration of artificial intelligence (AI) and big data analytics [79]. The increasing availability of large-scale genomic datasets, combined with the power of AI and machine learning algorithms, will enable clinicians to predict drug responses with unprecedented accuracy. AI can analyze complex genetic data from thousands of patients to identify patterns and correlations that would be impossible for humans to detect, providing clinicians with actionable insights that can guide treatment decisions [80].

Furthermore, the use of big data can facilitate the identification of new genetic biomarkers associated with drug response, enabling the development of more precise and personalized therapies. By integrating pharmacogenetic data with other types of patient data, such as electronic health records (EHRs), clinical trial data, and environmental factors, AI models can predict the most effective treatment strategies for individual patients, optimizing therapeutic outcomes and reducing ADRs [81].

The convergence of pharmacogenetics, AI, and big data holds enormous potential to transform the healthcare landscape, enabling a truly personalized approach to medicine that takes into account not only a patient's genetic makeup but also their unique health history, lifestyle, and environmental exposures [82].

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

5.3 The Promise of Global Precision Medicine Initiatives

As pharmacogenetics continues to evolve, its global implementation will be key to realizing its full potential. In recent years, large-scale international initiatives aimed at advancing precision medicine have gained momentum, such as the All of Us initiative in the United States, which seeks to gather diverse genetic data from millions of people to improve the understanding of health and disease [83].

Similarly, global collaborations such as the Global Alliance for Genomics and Health (GA4GH) are working to harmonize pharmacogenetic data across borders, enabling researchers and clinicians to access a wealth of genetic information that can inform drug development and clinical decision-making [84]. These initiatives hold the promise of creating a global network of pharmacogenetic data, allowing for more accurate and comprehensive insights into how genetic variation impacts drug response across different populations.

To ensure the equitable distribution of these benefits, however, there must be a concerted effort to address the disparities in access to pharmacogenetic testing and treatments between high- and low-income countries [85]. By promoting international collaboration, developing affordable testing platforms, and ensuring that the benefits of pharmacogenetics are available to all populations, we can move toward a future where precision medicine is accessible to everyone, regardless of their geographic location or socioeconomic status.

6. Clinical Applications of Pharmacogenetics

6.1 Precision Oncology: Tailoring Cancer Treatment Based on Genetic Profiles

One of the most significant successes of pharmacogenetics has been its integration into oncology, where genetic testing is used to tailor cancer treatments based on an individual's genetic makeup [86]. Cancer is driven by genetic mutations that affect cellular behavior, and these mutations can influence how a tumor responds to chemotherapy, targeted therapies, and immunotherapies. Pharmacogenetic testing allows clinicians to identify mutations in both the tumor and the patient's germline DNA, providing insights into the most effective treatment options.

For example, genetic tests can identify patients with specific mutations in the **EGFR** (epidermal growth factor receptor) gene, who are more likely to respond to targeted therapies like **erlotinib** or **gefitinib**. Similarly, **HER2-positive** breast cancer patients may benefit from **trastuzumab** (Herceptin) therapy. **BRCA1** and **BRCA2** mutations are also critical in selecting appropriate treatments, as patients with these mutations are often more responsive to therapies that induce DNA damage, such as **PARP inhibitors** [87].

Beyond the direct implications for treatment, pharmacogenetic testing in oncology also holds promise in identifying patients at higher risk of adverse drug reactions (ADRs). For instance, the **DPYD** gene variant can predict toxicity in patients treated with **5-fluorouracil** or its derivatives, helping to prevent serious side effects [88].

The expanding use of pharmacogenetics in cancer treatment has shown how genetic insights can guide personalized treatment regimens that are more effective and have fewer side effects, improving patient survival and quality of life. Continued research into cancer genomics, paired with the development of more affordable and accessible genetic testing technologies, is likely to further revolutionize oncology and make personalized cancer treatment the standard of care.

6.2 Cardiovascular Diseases: Optimizing Cardiovascular Drug Therapy

Pharmacogenetics also plays a critical role in managing cardiovascular diseases (CVDs), one of the leading causes of death worldwide. The genetic basis of drug responses in CVD treatments such as **statins**, **antiplatelets**, **beta-blockers**, and **antihypertensives** is increasingly recognized as essential for optimizing therapy.

Statins, commonly prescribed to lower cholesterol levels, are effective in preventing heart disease but are associated with adverse effects like muscle pain or myopathy in certain individuals, often linked to variations in the **SLCO1B1** gene [89]. Pharmacogenetic testing can help identify individuals at higher risk for these side effects, allowing clinicians to adjust statin doses or choose alternative medications, such as **ezetimibe** or **PCSK9 inhibitors**, based on genetic risk factors.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

Similarly, genetic testing for **CYP2C19** polymorphisms is crucial for patients receiving **clopidogrel**, a widely used antiplatelet medication. Individuals with certain variants of **CYP2C19** are poor metabolizers of the drug, leading to reduced effectiveness and an increased risk of thrombotic events [90]. Testing for these genetic variants allows healthcare providers to prescribe alternative antiplatelet medications, such as **ticagrelor** or **prasugrel**, which do not rely on **CYP2C19** for activation.

For patients with **hypertension**, variations in genes like **AGT** (angiotensinogen), **ACE** (angiotensin-converting enzyme), and **CYP3A5** can influence their response to antihypertensive medications. Pharmacogenetic testing can guide the selection of the most effective medication, whether it's an **ACE inhibitor**, **angiotensin receptor blocker (ARB)**, **calcium channel blocker**, or **diuretic**, based on an individual's genetic profile [91].

6.3 Psychiatry: Personalizing Mental Health Treatments

In psychiatry, pharmacogenetics is revolutionizing the treatment of psychiatric disorders by enabling clinicians to select medications based on an individual's genetic profile [92]. Mental health conditions such as depression, schizophrenia, bipolar disorder, and anxiety disorders often require long-term pharmacotherapy, with treatment responses varying greatly between individuals [93].

For example, patients with CYP2D6 polymorphisms may experience different metabolic rates when taking antidepressants such as SSRIs (selective serotonin reuptake inhibitors) or TCAs (tricyclic antidepressants), affecting both the efficacy and the risk of side effects [94]. Testing for CYP2D6 variations allows clinicians to tailor dosages or select alternative medications that are better suited to the patient's genetic profile [95].

Pharmacogenetics is also critical in the treatment of antipsychotic medications, which are frequently used to manage conditions such as schizophrenia and bipolar disorder. Variations in the CYP450 enzyme system, particularly CYP1A2, can affect the metabolism of clozapine and other antipsychotics, leading to either reduced effectiveness or dangerous side effects [96]. Pharmacogenetic testing allows psychiatrists to predict which medications will be most effective and least likely to cause adverse effects, leading to more targeted and personalized treatment regimens [97].

In the future, personalized psychiatry may include a comprehensive understanding of a patient's genetic, epigenetic, and environmental factors, offering a more holistic approach to mental health care [98]. The integration of pharmacogenetics into psychiatric practice holds great promise for improving patient outcomes and reducing the trial-and-error nature of current treatment strategies [99].

7. Pharmacogenetics and Global Healthcare Disparities

7.1 Genetic Diversity and the Global Applicability of Pharmacogenetics

One of the challenges facing the widespread implementation of pharmacogenetics is genetic diversity among different populations. Many pharmacogenetic studies have been conducted primarily in populations of European descent, leading to potential biases in the applicability of pharmacogenetic findings to other ethnic groups [100]. For example, certain genetic polymorphisms may be more prevalent in specific populations, such as the CYP2C19 gene variants, which have a higher frequency in Asian populations compared to those of European descent [101].

As pharmacogenetic research progresses, it is crucial to ensure that diverse populations are adequately represented in clinical trials and genetic studies to ensure the findings are applicable globally [102]. Initiatives like the Global Alliance for Pharmacogenomics (GAP) aim to create more inclusive pharmacogenetic databases that represent the genetic variability found in populations across the globe, including underrepresented groups in Africa, Asia, and Latin America [103]. These initiatives will be essential in developing universal pharmacogenetic guidelines that are relevant to all populations, helping to reduce health disparities related to genetic differences [104].

7.2 Improving Access to Pharmacogenetic Testing in Low-Resource Settings

Access to pharmacogenetic testing is currently limited, especially in low- and middle-income countries (LMICs), where healthcare systems may struggle with limited resources and infrastructure [105]. Although

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

pharmacogenetics has the potential to greatly improve patient care in these regions, the high cost of genetic testing and the lack of trained professionals to interpret the results pose significant barriers to its implementation [106].

Efforts to improve access include initiatives aimed at lowering the cost of genetic tests, developing point-of-care testing technologies, and training healthcare providers in the basics of pharmacogenetic testing and its interpretation [107]. The use of next-generation sequencing (NGS) technologies is becoming increasingly affordable and could provide a pathway for scaling pharmacogenetic testing in resource-limited settings [108]. In addition, the implementation of telemedicine and e-health platforms could enable remote consultations and testing interpretations, improving access to pharmacogenetic expertise in underserved regions [109].

To address these disparities, governments and international health organizations must invest in initiatives that promote global access to pharmacogenetic testing, ensuring that its benefits are available to all patients, regardless of their geographic location or economic status [110].

7.3 Policy and Regulatory Challenges in Pharmacogenetics

The widespread adoption of pharmacogenetics faces significant regulatory challenges, particularly around issues of privacy, data sharing, and reimbursement [111]. Given the sensitive nature of genetic data, policies must be developed to protect patient privacy and prevent the misuse of genetic information for non-medical purposes [112]. In addition, inconsistent regulations between countries on the use and reimbursement of pharmacogenetic tests have hindered global integration [113].

Establishing international standards and frameworks for the ethical use of pharmacogenetic data will be essential to facilitate its global implementation [114]. In parallel, healthcare policies need to evolve to support the reimbursement of pharmacogenetic testing, particularly in regions where genetic testing is not yet widely covered by insurance [115]. By addressing these regulatory challenges, pharmacogenetics can be integrated into mainstream healthcare systems worldwide [116].

8. Ethical and Legal Considerations in Pharmacogenetics

8.1 Informed Consent and Genetic Privacy

As pharmacogenetics becomes more integrated into everyday medical practice, ethical issues become especially significant [117]. A crucial aspect is informed consent, since genetic testing provides deep insights into a patient's genetic predispositions, which can have serious implications not only for the individual but also for their family [118].

Patients must clearly understand which genetic tests will be conducted, as well as the potential consequences of the results, including information that might not be directly related to the current medical issue [119]. For example, testing might reveal a predisposition to a disease the patient was unaware of, which can cause additional psychological and social issues [120]. It is important that patients are aware that they can opt out of receiving certain results if they don't relate to their current treatment [121].

On the other hand, genetic privacy is a major concern as the volume of genetic data increases [122]. If personal genetic data falls into the wrong hands, it could lead to consequences in insurance, employment, or social discrimination [123]. Stronger mechanisms for data protection and international standards need to be developed to prevent breaches of confidentiality and ensure compliance with medical ethics [124].

Laws such as the Genetic Information Non-Discrimination Act (GINA) in the U.S. have taken steps to protect individuals from genetic discrimination [125]. However, such laws are not universal, and in some countries, genetic information can lead to discrimination, highlighting the need for international legal frameworks to regulate the use of genetic data [126].

8.2 Genetic Discrimination and Social Stigma

Genetic discrimination remains a significant issue that extends beyond traditional medicine and into social and economic spheres [127]. For example, employers might reject candidates based on genetic tests that reveal predispositions to certain health conditions, even though the individual may not show any symptoms of the disease [128].

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

Social stigma is also a serious barrier, especially in cultures where genetic diseases are seen as incurable or inevitable [129]. For instance, learning about a predisposition to Alzheimer's disease could not only affect the individual but also their family, potentially lowering their social status or leading to exclusion from certain social groups [130].

To mitigate these negative effects, education programs are needed to foster an understanding of genetic information, so it is not viewed as a sentence but rather as a tool for prevention and early detection [131]. Public campaigns aimed at raising awareness of the ethical implications of genetic testing can help reduce social stigma and improve the public perception of genetic technologies [132].

8.3 Intellectual Property and Commercialization of Genetic Data

Commercialization of genetic data and intellectual property are becoming critical issues in pharmacogenetics, as large biotechnology and pharmaceutical companies can patent genes and genetic markers associated with drug responses [133]. These patents may restrict access to innovative genetic tests and treatments for patients, driving up healthcare costs and creating economic barriers for those who cannot afford such services [134].

Companies working with pharmacogenetic tests might also exacerbate the issue of monopolizing scientific data [135]. For example, patents on genetic markers related to drug metabolism may lead to only a few firms being able to produce drugs or tests, reducing competition and limiting access to innovative solutions [136]. Open databases where research results are accessible to all could help alleviate this issue and ensure fair access to genetic knowledge [137].

9. Future Directions in Pharmacogenetics

9.1 Integration of Pharmacogenetics into Routine Clinical Practice

One of the major directions for pharmacogenetics is its integration into routine clinical practice [138]. Currently, pharmacogenetics remains a specialized field, and genetic tests are only used in certain cases, such as cancer treatment or rare diseases [139]. However, with the increasing availability of genetic technologies and decreasing test costs, it becomes possible to use pharmacogenetic data for personalized drug prescriptions [140].

Key challenges clinicians face include the insufficient training of doctors to interpret genetic data and the lack of standardized protocols for its use in everyday practice [141]. Additionally, cost remains a barrier, as genetic testing can still be expensive for many patients [142]. In the future, successful integration of pharmacogenetics into medicine will require policies to lower the price of tests and include them in standard clinical protocols [143]. For pharmacogenetics to become part of everyday practice, new technologies must be implemented, and medical ethics need to evolve to prevent the excessive or unauthorized use of genetic data [144].

9.2 Precision Medicine and Multi-Omic Approaches

Pharmacogenetics' future lies in the integration not only of genetic information but also data from other omic fields, such as proteomics, metabolomics, and transcriptomics, to create a multi-level approach for personalized treatment [145]. For instance, metabolomics will help understand how the body processes drugs on a cellular level, and proteomics could identify biomarkers that predict drug responses more accurately [146]. Combining these diverse sources of data will allow clinicians to craft treatment regimens that are uniquely suited to each patient’s genetic, environmental, and biological profile [147].

Incorporating machine learning and artificial intelligence (AI) into pharmacogenetic research could significantly accelerate the identification of novel drug targets and predict the best therapeutic approaches for individuals [148]. Through these innovations, pharmacogenetics will move closer to being a comprehensive, all-encompassing approach to personalized medicine [149].

10. Conclusion

Pharmacogenetics is rapidly emerging as a cornerstone of personalized medicine, reshaping the way healthcare systems approach the treatment of diseases. By analyzing genetic variations that influence drug metabolism, efficacy, and toxicity, pharmacogenetics provides clinicians with the ability to make highly individualized decisions about drug selection, dosage, and treatment regimens. This enables the optimization

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

of therapeutic outcomes, reduces adverse drug reactions (ADRs), and shifts the paradigm from a trial-and-error approach to a more targeted, effective form of treatment.

The current landscape of pharmacogenetics has already shown immense promise in enhancing patient care, especially in complex disease areas like oncology, cardiology, psychiatry, and neurology. With the growing understanding of **genomic variation**, clinicians can now adjust drug prescriptions to match the genetic profiles of their patients, leading to a marked improvement in therapeutic efficacy. For example, **genetic testing for variants in the CYP450 family** of enzymes has led to more precise dosing of antidepressants, statins, and chemotherapy drugs, thereby reducing the risk of toxicity and improving patient outcomes. Likewise, in cancer therapy, the identification of genetic mutations in the **HER2** and **EGFR** receptors has resulted in the development of targeted therapies that have revolutionized cancer treatment, significantly improving survival rates.

However, as pharmacogenetics continues to gain traction in clinical settings, several key challenges must be addressed to fully realize its potential. **Ethical, legal, and social implications** remain at the forefront of discussions regarding the integration of pharmacogenetics into healthcare systems. Issues such as **genetic privacy**, **patient consent**, and the potential for **genetic discrimination** are important concerns that need to be thoroughly addressed. The protection of patients' genetic data is of paramount importance, requiring robust regulations and protocols to ensure the ethical handling of this sensitive information. Additionally, the **costs of genetic testing** and the **accessibility** of pharmacogenetic services remain significant barriers, particularly in low-resource settings, which could limit the widespread implementation of personalized medicine on a global scale. Addressing these disparities is critical to ensuring equitable access to pharmacogenetic advances and to avoid exacerbating existing healthcare inequalities.

Moreover, the complexity of **gene-environment interactions** presents another layer of difficulty in implementing pharmacogenetic-based therapies. Environmental factors such as diet, lifestyle, and exposure to pollutants can significantly influence drug metabolism and response. The integration of **multi-omic data**, encompassing genomics, proteomics, metabolomics, and environmental data, offers a more comprehensive understanding of how individuals respond to medications. This integrated approach could help overcome the limitations of a purely genetic model, further enhancing the precision of personalized medicine.

Despite these challenges, the **future of pharmacogenetics** holds tremendous promise. As the field continues to evolve, we are witnessing the emergence of **novel technologies** such as **CRISPR/Cas9 gene editing** and **single-cell sequencing**, which may dramatically improve our understanding of genetic underpinnings of drug responses and lead to more personalized and targeted therapies. **Artificial intelligence** (AI) and **machine learning** also offer powerful tools for analyzing vast amounts of genetic, clinical, and environmental data, enabling clinicians to predict drug responses with unprecedented accuracy and efficiency. These technologies could revolutionize the drug discovery process, accelerating the identification of new drug targets and optimizing clinical trial design.

The integration of pharmacogenetics into routine clinical practice will likely be driven by **standardized clinical guidelines** and **evidence-based protocols**. The establishment of comprehensive guidelines, such as those provided by the **Clinical Pharmacogenetics Implementation Consortium (CPIC)**, has already been a step in the right direction. These guidelines provide clear recommendations for clinicians on how to implement pharmacogenetic testing in drug prescribing, particularly for drugs with known genetic markers, such as warfarin, clopidogrel, and carbamazepine. Widespread adoption of such guidelines will lead to more consistent and informed decision-making, enhancing the quality of care delivered to patients.

As pharmacogenetics continues to grow, its focus must shift not only to improving drug selection and dosing but also to **preventive medicine**. By identifying genetic predispositions to certain diseases, pharmacogenetic testing can offer insights into disease prevention, early diagnosis, and the development of personalized prevention strategies. Early identification of individuals at higher risk for conditions such as cardiovascular

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

disease, diabetes, or certain cancers can lead to personalized lifestyle modifications and interventions that could delay or even prevent the onset of these diseases.

In **oncology**, the role of pharmacogenetics has been groundbreaking, with the discovery of **genetic biomarkers** that guide the choice of cancer therapies. The use of **biomarkers such as EGFR, HER2, and KRAS mutations** has transformed the landscape of cancer treatment, allowing for **targeted therapies** that not only enhance efficacy but also minimize side effects. Ongoing research into the molecular genetics of cancer will likely uncover even more biomarkers that can be used to tailor therapies to individual tumor profiles, paving the way for truly **personalized oncology**.

In **cardiology**, pharmacogenetic advancements hold the potential to improve the management of **hypertension**, **arrhythmias**, and **heart failure**. By understanding the genetic factors influencing drug metabolism, clinicians can fine-tune therapies such as beta-blockers, ACE inhibitors, and statins to achieve optimal therapeutic effects. In the future, pharmacogenetic testing could be routinely used to determine the most effective cardiovascular medications for patients, leading to better outcomes and reduced incidence of adverse events.

The path forward for pharmacogenetics will require **collaboration across multiple disciplines**—from genetics and bioinformatics to healthcare providers and policymakers. Integrating pharmacogenetics into medical education, healthcare infrastructure, and routine clinical practice will be essential in realizing the full potential of personalized medicine. **Interdisciplinary collaboration** will facilitate the development of better tools for genetic testing, improve the implementation of pharmacogenetic data into clinical workflows, and enhance the overall effectiveness of personalized treatments.

The next decade promises to be an exciting time for pharmacogenetics. The continuing expansion of genomic databases, coupled with advances in computational technologies and **artificial intelligence**, will provide deeper insights into the genetic factors that influence drug response. The resulting discoveries will enable the development of more **precise, effective, and safer therapies** across a wide range of diseases, particularly those with complex genetic underpinnings.

In summary, pharmacogenetics holds the potential to transform medicine into a more **precise, individualized, and patient-centered discipline**, offering the promise of **better outcomes, fewer adverse reactions**, and **more effective treatments**. With continued research, integration into clinical practice, and the overcoming of current barriers, pharmacogenetics will pave the way for the future of personalized healthcare—one that is more **scientifically informed, ethically grounded**, and **equally accessible** for all.

References

1.Shnayder, N.A.; Grechkina, V.V.; Khasanova, A.K.; Bochanova, E.N.; Dontceva, E.A.; Petrova, M.M.; Asadullin, A.R.; Shipulin, G.A.; Altynbekov, K.S.; Al-Zamil, M.; et al. Therapeutic and toxic effects of valproic acid metabolites. *Metabolites* **2023**, *13*, 134.

[CrossRef] [PubMed]

2.Shnayder, N.A.; Grechkina, V.V.; Trefilova, V.V.; Efremov, I.S.; Dontceva, E.A.; Narodova, E.A.; Petrova, M.M.; Soloveva, I.A.; Tepnadze, L.E.; Reznichenko, P.A.; et al. Valproate-induced metabolic syndrome. *Biomedicines* **2023**, *11*, 1499. [CrossRef] [PubMed]

3.Nasyrova, R.F.; Ivanov, M.V.; Neznanov, N.G. *Introduction to Psychopharmacogenetics*; Publishing Center of V.M. Bekhterev: St. Petersburg, Russia, 2015; p. 272.

4.Safdar, A.; Ismail, F. A comprehensive review on pharmacological applications and drug-induced toxicity of valproic acid. *Saudi Pharm. J.* **2023**, *31*, 265–278. [CrossRef] [PubMed]

5.Shnaider, N.A.; Dmitrenko, D.V. Chronic valproic acid intoxication in epileptology: Diagnosis and treatment. *Neurol. Neuropsychi atry Psychosom.* **2016**, *8*, 94–99. (In Russian) [CrossRef]

6.Iannaccone, T.; Sellitto, C.; Manzo, V.; Colucci, F.; Giudice, V.; Stefanelli, B.; Iuliano, A.; Corrivetti, G.; Filippelli, A. Pharmacoge netics of carbamazepine and valproate: Focus on polymorphisms of drug

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

metabolizing enzymes and transporters. *Pharmaceuticals* **2021**, *14*, 204. [CrossRef]

7. Caudle, K.E.; Dunnenberger, H.M.; Freimuth, R.R.; Peterson, J.F.; Burlison, J.D.; Whirl-Carrillo, M.; Scott, S.A.; Rehm, H.L.; Williams, M.S.; Klein, T.E.; et al. Standardizing terms for clinical pharmacogenetic test results: Consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). *Genet. Med. Off. J. Am. Coll. Med. Genet.* **2017**, *19*, 215–223. [CrossRef] [PubMed]

8. Brouwer, J.M.J.L.; Nijenhuis, M.; Soree, B.; Guchelaar, H.J.; Swen, J.J.; van Schaik, R.H.N.; Weide, J.V.; Rongen, G.A.P.J.M.; Buunk, A.M.; de Boer-Veger, N.J.; et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. *Eur. J. Hum. Genet. EJHG* **2022**, *30*, 1114–1120. [CrossRef] [PubMed]

9. Bochanova, E.A.; Gusev, S.D. The frequency and structure of adverse drug reactions in the pharmacotherapy of epilepsy. *Pers. Psychiatry Neurol.* **2024**, *4*, 18–25. [CrossRef]

10. Malygin, A.S.; Popov, N.S.; Demidova, M.A.; Kudryashova, M.N. Chromatography-tandem MASS spectrometry (HPLC-MS/MS) for the detection of valproic acid and its metabolites in blood plasma. *Epilepsy Paroxysmal Cond.* **2018**, *10*, 35–42. [CrossRef]

11. Damegunta, S.R. Time Matters!: When is the right time to estimate serum valproic acid levels? *Indian J. Psychol. Med.* **2014**, *36*, 349–350. [CrossRef]

12. Miroshnichenko, I.I.; Baymeeva, N.V.; Platova, A.I. Determination of serum/plasma concentrations of psychotropic drugs in therapeutic drug monitoring. *Pharmacokinet. Pharmacodinamics* **2021**, *1*, 3–13. [CrossRef]

13. Reed, R.C.; Dutta, S. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER? *Ther. Drug Monit.* **2006**, *28*, 413–418. [CrossRef] [PubMed]

14. Pagana, K.D.; Pagana, T.J.; Pagana, T.N. *Mosby's Diagnostic & Laboratory Test Reference*; Elsevier: St. Louis, MO, USA, 2019; p. 14.

15. Valproic Acid: The Test. Available online: http://labtestsonline.org/understanding/analytes/valproic-acid/tab/test (accessed on 12 December 2023).

16. Brunton, L.L.; Chabner, B.A.; Knollmann, B.C. Pharmacotherapy of the Epilepsies, Valproic Acid. In *Goodman & Gilman's the Pharmacological Basis of Therapeutics*; The McGraw-Hill Companies: New York, NY, USA, 2011; Chapter 12; p. 21.

17. Wu, X.; Dong, W.; Li, H.; Yang, X.; Jin, Y.; Zhang, Z.; Jiang, Y. CYP2C9*3/*3 gene expression affects the total and free concentrations of valproic acid in pediatric patients with epilepsy. *Pharmgenom. Pers. Med.* **2021**, *14*, 417–430. [CrossRef]

18. Sabin, O.; Pop, R.; Trifa, A.; Buzoianu, A.D. The influence of CYP2C9, CYP2C19 and ABCB1 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. *Int. J. Bioflux Soc.* **2016**, *8*, 29–33.

19. Song, C.; Li, X.; Mao, P.; Song, W.; Liu, L.; Zhang, Y. Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy. *Eur. J. Hosp. Pharm.* **2022**, *29*, 198–201. [CrossRef] [PubMed]

20. Vlasov, P.N.; Orekhova, N.V.; Antoniuk, M.V.; Filatova, N.V.; Shnayder, N.A.; Dmitrenko, D.V.; Zobova, S.N.; Poverennova, I.E.; Yakunina, A.V.; Kalinin, V.A.; et al. Efficacy and safety of valproic acid preparations with delayed release of active substance in adults in real clinical practice from the position of pharmacokinetic and pharmacogenetic approach. *Neurol. Neuropsychiatry Psychosom.* **2017**, *9* (Suppl. 1), 11–20. [CrossRef]

21. Kantemirova, B.I.; Starodubtsev, A.K.; Sychev, D.A.; Belopasov, B.B.; Tsotsonava, J.M.; Griganov, V.I. Ways of improvement of pharmacotherapy of epilepsy in children: Focus on specific features of drug biotransformation. *Epilepsy Paroxysmal Cond.* **2012**, *4*, 14–18.

22. Moskaleva, P.V.; Shnayder, N.A.; Nasyrova, R.F. Timing of pharmacogenetic testing: Before or after

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

the development of adverse drug reactions? *Pharmacogenet. Pharmacogenom.* **2018**, *2*, 56–57.

23. Wang, C.; Wang, P.; Yang, L.P.; Pan, J.; Yang, X.; Ma, H.Y. Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy. *Epilepsy Res.* **2017**, *132*, 64–69. [CrossRef]

24. Wang, S.; Li, J.; Song, M.; Yan, P.; Ju, X.; Liu, J.; Wang, C.; Shi, J. Effect of CYP2C19 polymorphisms on serum valproic level acid in Chinese Han patients with schizophrenia. *Sci. Rep.* **2021**, *11*, 23150. [CrossRef]

25. Narjis, M.; Nada, M.; Mujeeb, U.S. Pharmacokinetic mechanisms underlying clinical cases of valproic acid autoinduction: A review. *J. Affect. Disord. Rep.* **2022**, *10*, 100426. [CrossRef]

26. Fang, H.; Wang, X.; Hou, K.; Zhang, Y.; Shao, S.; Zhang, G.; Feng, Y.; Huang, L. The association of adjusted plasma valproic acid concentration with *CYP2C9* gene polymorphism in patients with epilepsy: A systematic review and meta-analysis. *Ann. Transl. Med.* **2021**, *9*, 846. [CrossRef] [PubMed]

27. Manikandan, P.; Nagini, S. Cytochrome P450 structure, function and clinical significance: A review. *Curr. Drug Targets* **2018**, *19*, 38–54. [CrossRef] [PubMed]

28. Shnayder, N.A.; Abdyrakhmanova, A.K.; Nasyrova, R.F. Oxidation of antipsychotics. *Encyclopedia* **2022**, *2*, 974–989. [CrossRef]

29. Shnayder, N.A.; Abdyrakhmanova, A.K.; Nasyrova, R.F. Phase I of antipsychotics metabolism and its pharmacogenetic testing. *Pers. Psychiatry Neurol.* **2022**, *2*, 4–21. [CrossRef]

30. Guengerich, F.P. Mechanisms of cytochrome P450-catalyzed oxidations. *ACS Catal.* **2018**, *8*, 10964–10976. [CrossRef] [PubMed]

31. Zhao, M.; Ma, J.; Li, M.; Zhang, Y.; Jiang, B.; Zhao, X.; Huai, C.; Shen, L.; Zhang, N.; He, L.; et al. Cytochrome P450 enzymes and drug metabolism in humans. *Int. J. Mol. Sci.* **2021**, *22*, 12808. [CrossRef] [PubMed]

32. Tsukahara, M.; So, R.; Yoshimura, Y.; Yamashita, R.; Yada, Y.; Kodama, M.; Nakajima, S.; Kishi, Y.; Takeda, T.; Yamada, N.; et al. Effect of smoking habits and concomitant valproic acid use on relapse in patients with treatment-resistant schizophrenia receiving clozapine: A 1-year retrospective cohort study. *Acta Psychiatr. Scand.* **2023**, *148*, 437–446. [CrossRef] [PubMed]

33. Mondragón-Jiménez, J.F.; Ojeda-Lara, B.; Alvarez-Aguilar, A.; Brito-Pérez, C.A.; Rosales-Hernández, F.J.; González-Pérez, M. Interaction of valproic acid vs. neurotransmitters and the relationship to nicotine by the quantum method. *World J. Pharm. Res.* **2017**, *6*, 96–103. [CrossRef]

34. Drokov, A.P.; Lipatova, L.V.; Shnayder, N.A.; Nasyrova, R.F. Pharmacogenetic Markers for Metabolic Impairments in Treatment with Valproic Acid. *Neurosci. Behav. Phys.* **2020**, *50*, 13–19. [CrossRef]

35. Jia, Y.; Tang, L.; Yao, Y.; Zhuo, L.; Qu, D.; Chen, X.; Ji, Y.; Tao, J.; Zhu, Y. Low-intensity exercise combined with sodium valproate attenuates kainic acid-induced seizures and associated co-morbidities by inhibiting NF-κB signaling in mice. *Front. Neurol.* **2022**, *13*, 993405. [CrossRef] [PubMed]

36. Zhang, L.F.; Liu, L.S.; Chu, X.M.; Xie, H.; Cao, L.J.; Guo, C.; A, J.Y.; Cao, B.; Li, M.J.; Wang, G.J.; et al. Combined effects of a high-fat diet and chronic valproic acid treatment on hepatic steatosis and hepatotoxicity in rats. *Acta Pharmacol. Sin.* **2014**, *35*, 363–372. [CrossRef]

37. Zhu, M.M.; Li, H.L.; Shi, L.H.; Chen, X.P.; Luo, J.; Zhang, Z.L. The pharmacogenomics of valproic acid. *J. Hum. Genet.* **2017**, *62*, 1009–1014. [CrossRef] [PubMed]

38. Ellisy, R.A.; Bakri, A.H.; Mangoura, S.A.; Abdelraheem, M.H.; Farghaly, H.S. Genetic polymorphisms associated with valproic acid therapy: Review article. *SVU-Int. J. Med. Sci.* **2022**, *5*, 355–361. [CrossRef]

39. Verrotti, A.; Mencaroni, E.; Cofini, M.; Castagnino, M.; Leo, A.; Russo, E.; Belcastro, V. Valproic acid metabolism and its consequences on sexual

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

functions. *Curr. Drug Metab.* **2016**, *17*, 573–581. [CrossRef] [PubMed]

40. Gotlib, D.; Ramaswamy, R.; Kurlander, J.E.; DeRiggi, A.; Riba, M. Valproic acid in women and girls of childbearing age. *Curr. Psychiatry Rep.* **2017**, *19*, 58. [CrossRef] [PubMed]

41. Glauser, T.A.; Cnaan, A.; Shinnar, S.; Hirtz, D.G.; Dlugos, D.; Masur, D.; Clark, P.O.; Adamson, P.C. Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: Initial monotherapy outcomes at 12 months. *Epilepsia* **2013**, *54*, 141–155. [CrossRef]

42. Stephen, J. Drug treatment of epilepsy in elderly people: Focus on valproic Acid. *Drugs Aging* **2003**, *20*, 141–152. [CrossRef]

43. Perucca, E.; Aldenkamp, A.; Tallis, R.; Krämer, G. Role of valproate across the ages. Treatment of epilepsy in the elderly. *Acta Neurol. Scand. Suppl.* **2006**, *184*, 28–37. [CrossRef]

44. Meseguer, E.S.; Elizalde, M.U.; Borobia, A.M.; Ramírez, E. Valproic Acid-Induced Liver Injury: A Case-Control Study from a Prospective Pharmacovigilance Program in a Tertiary Hospital. *J. Clin. Med.* **2021**, *10*, 1153. [CrossRef]

45. *LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]*; National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA, 2012; Updated 2020. Available online: https://www.ncbi.nlm.nih.gov/books/NBK548284 (accessed on 10 March 2024).

46. Ruiz-Giménez, J.; Sánchez-Alvarez, J.C.; Cañadillas-Hidalgo, F.; Serrano-Castro, P.J. Andalusian Epilepsy Society. Antiepileptic treatment in patients with epilepsy and other comorbidities. *Seizure* **2010**, *19*, 375–382. [CrossRef] [PubMed]

47. de Leon, J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: Pharmacological issues and further understanding. *Rev. Psiquiatr. Salud Ment.* **2015**, *8*, 167–188. [CrossRef] [PubMed]

48. Gunes, A.; Bilir, E.; Zengil, H.; Babaoglu, M.O.; Bozkurt, A.; Yasar, U. Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. *Basic Clin. Pharmacol. Toxicol.* **2007**, *100*, 383–386. [CrossRef] [PubMed]

49. Chiarella, P.; Capone, P.; Sisto, R. Contribution of Genetic Polymorphisms in Human Health. *Int. J. Environ. Res. Public Health* **2023**, *20*, 912. [CrossRef] [PubMed]

50. Sakaguchi, N.; Suyama, M. In silico identification of pseudo-exon activation events in personal genome and transcriptome data. *RNA Biol.* **2021**, *18*, 382–390. [CrossRef] [PubMed]

51. Zou, H.; Wu, L.X.; Tan, L.; Shang, F.F.; Zhou, H.H. Significance of Single-Nucleotide Variants in Long Intergenic Non-protein Coding RNAs. *Front. Cell Dev. Biol.* **2020**, *8*, 347. [CrossRef] [PubMed]

52. Botton, M.R.; Whirl-Carrillo, M.; Del Tredici, A.L.; Sangkuhl, K.; Cavallari, L.H.; Agúndez, J.A.G.; Duconge, J.; Lee, M.T.M.; Woodahl, E.L.; Claudio-Campos, K.; et al. PharmVar GeneFocus: CYP2C19. *Clin. Pharmacol. Ther.* **2021**, *109*, 352–366. [CrossRef] [PubMed]

53. Kumondai, M.; Hishinuma, E.; Gutiérrez Rico, E.M.; Ito, A.; Nakanishi, Y.; Saigusa, D.; Hirasawa, N.; Hiratsuka, M. Heterologous expression of high-activity cytochrome P450 in mammalian cells. *Sci. Rep.* **2020**, *10*, 14193. [CrossRef]

54. Giantin, M.; Rahnasto-Rilla, M.; Tolosi, R.; Lucatello, L.; Pauletto, M.; Guerra, G.; Pezzato, F.; Lopparelli, R.M.; Merlanti, R.; Carnier, P.; et al. Functional impact of cytochrome P450 3A (CYP3A) missense variants in cattle. *Sci. Rep.* **2019**, *9*, 19672. [CrossRef]

55. Deng, N.; Zhou, H.; Fan, H.; Yuan, Y. Single nucleotide polymorphisms and cancer susceptibility. *Oncotarget* **2017**, *8*, 110635–110649. [CrossRef]

56. Rigau, M.; Juan, D.; Valencia, A.; Rico, D. Intronic CNVs and gene expression variation in human populations. *PLoS Genet.* **2019**, *15*, e1007902. [CrossRef] [PubMed]

57. Taleb, A.; Lin, W.; Xu, X.; Zhang, G.; Zhou, Q.G.; Naveed, M.; Meng, F.; Fukunaga, K.; Han, F.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

Emerging mechanisms of valproic acid-induced neurotoxic events in autism and its implications for pharmacological treatment. *Biomed. Pharmacother.* **2021**, *137*, 111322. [CrossRef]

58. Lin, Y.L.; Bialer, M.; Cabrera, R.M.; Finnell, R.H.; Wlodarczyk, B.J. Teratogenicity of valproic acid and its constitutional isomer,

amide derivative valnoctamide in mice. *Birth Defects Res.* **2019**, *111*, 1013–1023. [CrossRef]

59. Nasyrova, R.F.; Neznanov, N.G. *Clinical Psychopharmacogenetics*; DEAN: St. Petersburg, Russia, 2019; p. 405.

60. Nasyrova, R.F.; Sivakova, N.A.; Lipatova, L.V.; Ivashchenko, D.V.; Sosina, K.A.; Drokov, A.P.; Shnayder, N.A. Biological markers of efficacy and safety of antiepileptic drugs: Pharmacogenetics and pharmacokinetics. *Sib. Med. Rev.* **2017**, *103*, 17–25. (In Russian) [CrossRef]

61. Monti, B.; Polazzi, E.; Contestabile, A. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. *Curr. Mol. Pharmacol.* **2009**, *2*, 95–109. [CrossRef] [PubMed]

62. Santos, D.S.; Rocha, M.A.; Mello, M.L.S. Epigenetic studies in insects and the valproic acid perspective. *Braz. J. Biol.* **2022**, *84*, e256045. [CrossRef] [PubMed]

63. B″udi, T.; Tóth, K.; Nagy, A.; Szever, Z.; Kiss, Á.; Temesvári, M.; Háfra, E.; Garami, M.; Tapodi, A.; Monostory, K. Clinical significance of CYP2C9-status guided valproic acid therapy in children. *Epilepsia* **2015**, *56*, 849–855. [CrossRef] [PubMed]

64. Zhou, H.H.; Liu, Z.Q. Ethnic differences in drug metabolism. *Clin. Chem. Lab. Med.* **2000**, *38*, 899–903. [CrossRef]

65. SNPedia. Available online: http://www.SNPedia.com (accessed on 8 December 2023).

66. Marcus, J.; Novembre, J.; Tharsen, J.; Mueller, A. Geography of Genetic Variants Browser. Department of Human Genetics, University of Chicago. Available online: https://popgen.uchicago.edu/ggv/?data=%221000genomes%22&chr=1&pos=22208783 3 (accessed on 15 February 2024).

67. National Library of Medicine. Available online: https://www.ncbi.nlm.nih.gov/ (accessed on 15 January 2023).

68. Online Mendelian Inheritance in Man (OMIM®) 1966–2023, Johns Hopkins University. Available online: https://omim.org (accessed on 10 February 2024).

69. The Human Protein Atlas. Available online: https://www.proteinatlas.org/ (accessed on 23 January 2024).

70. Francis Lam, Y.W. Chapter 1—Principles of Pharmacogenomics: Pharmacokinetic, Pharmacodynamic, and Clinical Implications. In *Pharmacogenomics*, 2nd ed.; Elsevier: Amsterdam, The Netherlands, 2019; pp. 1–53. [CrossRef]

71. Safaa, M.; Alsanosi, M.; Skiffington, C.; Padmanabhan, S. Chapter 17—Pharmacokinetic Pharmacogenomics. In *Handbook of Pharmacogenomics and Stratified Medicine*; Elsevier: Amsterdam, The Netherlands, 2014; pp. 341–364. [CrossRef]

72. Kiang, T.K.; Ho, P.C.; Anari, M.R.; Tong, V.; Abbott, F.S.; Chang, T.K. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. *Toxicol. Sci.* **2006**, *94*, 261–271. [CrossRef]

73. Tornio, A.; Backman, J.T. Cytochrome P450 in Pharmacogenetics: An Update. *Adv. Pharmacol.* **2018**, *83*, 3–32. [CrossRef]

74. Schaffenburg, W.C.; Lockshin, B.N.; DeKlotz, C.M.C. Chapter 3—Polymorphisms: Why Individual Drug Responses Vary. In *Comprehensive Dermatologic Drug Therapy*, 4th ed.; Elsevier: Amsterdam, The Netherlands, 2021; pp. 21–33.e2. [CrossRef]

75. Vuppalanchi, R.M. Chapter 22—Metabolism of Drugs and Xenobiotics. In *Practical Hepatic Pathology: A Diagnostic Approach*, 2nd ed.; Elsevier: Amsterdam, The Netherlands, 2018; pp. 319–326. [CrossRef]

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

76. Langmia, I.M.; Just, K.S.; Yamoune, S.; Brockmöller, J.; Masimirembwa, C.; Stingl, J.C. CYP2B6 Functional variability in drug metabolism and exposure across populations-implication for drug safety, dosing, and individualized therapy. *Front. Genet.* **2021**, *12*, 692234. [CrossRef] [PubMed]

77. Dasgupta, A. Chapter 4—Genetic Factors Associated With Opioid Therapy and Opioid Addiction. In *Fighting the Opioid Epidemic*; Elsevier: Amsterdam, The Netherlands, 2020; pp. 61–88. [CrossRef]

78. Sparreboom, A.; Evans, W.E.; Baker, S.D. 6—Chemotherapy in the Pediatric Patient. In *Oncology of Infancy and Childhood*; Elsevier: Amsterdam, The Netherlands, 2009; pp. 173–207. [CrossRef]

79. Mittal, B.; Tulsyan, S.; Kumar, S.; Mittal, R.D.; Agarwal, G. Cytochrome P450 in Cancer Susceptibility and Treatment. *Adv. Clin. Chem.* **2015**, *71*, 77–139. [CrossRef] [PubMed]

80. Sangkuhl, K.; Claudio-Campos, K.; Cavallari, L.H.; Agundez, J.A.G.; Whirl-Carrillo, M.; Duconge, J.; Del Tredici, A.L.; Wadelius, M.; Rodrigues Botton, M.; Woodahl, E.L.; et al. PharmVar GeneFocus: CYP2C9. *Clin. Pharmacol. Ther.* **2021**, *110*, 662–676.

81. Van Booven, D.; Marsh, S.; McLeod, H.; Carrillo, M.W.; Sangkuhl, K.; Klein, T.E.; Altman, R.B. Cytochrome P450 2C9-CYP2C9. *Pharmacogenet. Genom.* **2010**, *20*, 277–281. [CrossRef] [PubMed]

82. Zhou, Y.; Nevosadová, L.; Eliasson, E.; Lauschke, V.M. Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences. *Hum. Genom.* **2023**, *17*, 15. [CrossRef] [PubMed]

83. Amini-Shirazi, N.; Ghahremani, M.H.; Ahmadkhaniha, R.; Mandegary, A.; Dadgar, A.; Abdollahi, M.; Shadnia, S.; Pakdaman, H.; Kebriaeezadeh, A. Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients. *Toxicol. Mech. Methods* **2010**, *20*, 452–457. [CrossRef] [PubMed]

84. Ho, P.C.; Abbott, F.S.; Zanger, U.M.; Chang, T.K. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. *Pharmacogenom. J.* **2003**, *3*, 335–342. [CrossRef]

85. Yoon, H.Y.; Ahn, M.H.; Yee, J.; Lee, N.; Han, J.M.; Gwak, H.S. Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: A meta-analysis. *Eur. J. Clin. Pharmacol.* **2020**, *76*, 1053–1058. [CrossRef]

86. Umamaheswaran, G.; Deepak, G.S. Chapter 46—Pharmacogenomics in India. In *Handbook of Pharmacogenomics and Stratified Medicine*; Elsevier: Amsterdam, The Netherlands, 2014; pp. 1037–1059. [CrossRef]

87. Cacabelos, R.; Cacabelos, P.; Torrellas, C. Chapter 27—Personalized Medicine of Alzheimer's Disease. In *Handbook of Pharmacogenomics and Stratified Medicine*; Elsevier: Amsterdam, The Netherlands, 2014; pp. 563–615. [CrossRef]

88. Shao, Z.; Kyriakopoulou, L.G.; Ito, S. Chapter 14—Pharmacogenomics. In *Handbook of Analytical Separations*; Elsevier: Amsterdam, The Netherlands, 2020; pp. 321–353. [CrossRef]

89. Nebert, D.W.; Zhang, G. Chapter 16—Pharmacogenomics. In *Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics*, 7th ed.; Elsevier: Amsterdam, The Netherlands, 2019; pp. 445–486. [CrossRef]

90. Dehbozorgi, M.; Kamalidehghan, B.; Hosseini, I.; Dehghanfard, Z.; Sangtarash, M.H.; Firoozi, M.; Ahmadipour, F.; Meng, G.Y.; Houshmand, M. Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (-806 C>T) alleles among an Iranian population of different ethnicities. *Mol. Med. Rep.* **2018**, *17*, 4195–4202. [CrossRef]

91. Payan, M.; Tajik, N.; Rouini, M.R.; Ghahremani, M.H. Genotype and allele frequency of CYP2C19*17 in a healthy Iranian population. *Med. J. Islam. Repub. Iran* **2015**, *29*, 269. [PubMed]

92. Wolf, K.K.; Paine, M.F.; Watkins, P.B. Chapter 10.05—Metabolic barrier of the gastrointestinal tract. In *Comprehensive Toxicology*, 2nd ed.; Elsevier:

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

Amsterdam, The Netherlands, 2010; pp. 53–75. [CrossRef]

93. Kawakami, M.; Takenoshita-Nakaya, S.; Takeba, Y.; Nishimura, Y.; Oda, M.; Watanabe, M.; Ohta, Y.; Kobayashi, S.; Ohtsubo, T.; Kobayashi, S.; et al. Evaluation of CYP2D6 protein expression and activity in the small intestine to determine its metabolic capability in the Japanese population. *Biol. Pharm. Bull.* **2017**, *40*, 1344–1351. [CrossRef] [PubMed]

94. Demkow, U. Chapter 11—Next generation sequencing in pharmacogenomics. In *Clinical Applications for Next-Generation Sequencing*; Elsevier: Amsterdam, The Netherlands, 2016; pp. 217–240. [CrossRef]

95. McGraw, J. Chapter 16—CYP450 and ethnicity. In *Handbook of Pharmacogenomics and Stratified Medicine*; Elsevier: Amsterdam, The Netherlands, 2014; pp. 323–340. [CrossRef]

96. Hebert, M.F. Chapter 3—Impact of pregnancy on maternal pharmacokinetics of medications. In *Clinical Pharmacology during Pregnancy*; Elsevier: Amsterdam, The Netherlands, 2013; pp. 17–39. [CrossRef]

97. Zobova, S.N.; Dmitrenko, D.V.; Shnayder, N.A.; Yakovleva, K.D.; Pervunina, A.V.; Pravdin, D.E.; Prusova, T.I. Role of carriage of single nucleotide variants of CYP2D6 and ABCB1 genes in the effectiveness of therapy with valproic acid preparations in patients with epilepsy. *Pharmacogenet. Pharmacogenom.* **2019**, *2*, 12. [CrossRef]

98. Varela, N.M.; Cerpa, L.C.; Martínez, M.M.; Quiñones, L.A. Pharmacogenomics: Genetic Polymorphisms. In *The ADME Encyclopedia*; Springer: Cham, Switzerland, 2021. [CrossRef]

99. Just, K.S.; Dormann, H.; Freitag, M.; Schurig, M.; Böhme, M.; Steffens, M.; Scholl, C.; Seufferlein, T.; Graeff, I.; Schwab, M.; et al. CYP2D6 in the Brain: Potential Impact on Adverse Drug Reactions in the Central Nervous System-Results from the ADRED Study. *Front. Pharmacol.* **2021**, *12*, 624104. [CrossRef] [PubMed]

100. Chattopadhyay, M.; Chowdhury, A.R.; Feng, T.; Assenmacher, C.A.; Radaelli, E.; Guengerich, F.P.; Avadhani, N.G. Mitochondrially targeted cytochrome P450 2D6 is involved in monomethylamine-induced neuronal damage in mouse models. *J. Biol. Chem.* **2019**, *294*, 10336–10348. [CrossRef] [PubMed]

101. Seripa, D.; Lozupone, M.; Stella, E.; Paroni, G.; Bisceglia, P.; La Montagna, M.; D'onofrio, G.; Gravina, C.; Urbano, M.; Priore, M.G.; et al. Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know? *Expert Opin. Drug Saf.* **2017**, *6*, 1373–1385. [CrossRef] [PubMed]

102. Molden, E.; Juki´c, M.M. *CYP2D6* Reduced Function Variants and Genotype/Phenotype Translations of CYP2D6 Intermediate Metabolizers: Implications for Personalized Drug Dosing in Psychiatry. *Front. Pharmacol.* **2021**, *12*, 650750. [CrossRef] [PubMed]

103. Shnayder, N.A.; Bochanova, E.N.; Dmitrenko, D.V.; Nasyrova, R.F. Pharmacogenetics of carbamazepine. *Epilepsy Paroxysmal Cond.* **2019**, *11*, 364–378. [CrossRef]

104. Shnayder, N.A.; Dmitrenko, D.V.; Pilugina, M.S. The pharmacogenetics antiepileptic drugs. *Bull. Sib. Med.* **2008**, *7*, 111–119.

105. Yakunina, A.V.; Povernova, I.E. The role of therapeutic drug monitoring in the use of antiepileptic drugs. *Epilepsy Paroxysmal Cond.* **2016**, *8*, 66–73. [CrossRef]

106. Zhu, X.; Li, X.; Zhang, T.; Zhao, L. Risk Factors for valproic acid-induced hyperammonaemia in Chinese paediatric patients with epilepsy. *Basic Clin. Pharmacol. Toxicol.* **2018**, *123*, 628–634. [CrossRef]

107. Nimesh, S.; Tomar, R.; Kumar, M.; Tyagi, N.; Shukla, P.K. A pharmacovigilance study of monitoring & focusing of adverse drug reactions induced by antiepileptic drugs used in epileptic patients. *Pharm. Pharmacol. Int. J.* **2019**, *7*, 100–104. [CrossRef]

108. Lara, D.V.; Melo, D.O.; Silva, R.A.M.; Santos, P.C.J.L. Pharmacogenetic testing in psychiatry and

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

neurology: An overview of reviews. *Pharmacogenomics* **2021**, *22*, 505–513. [CrossRef] [PubMed]

109. van Schaik, R.H.N.; Müller, D.J.; Serretti, A.; Ingelman-Sundberg, M. Pharmacogenetics in psychiatry: An update on clinical usability. *Front. Pharmacol.* **2020**, *11*, 575540. [CrossRef]

110. Hippman, C.; Nislow, C. Pharmacogenomic testing: Clinical evidence and implementation challenges. *J. Pers. Med.* **2019**, *9*, 40.

[CrossRef] [PubMed]

111. Srinivasan, S.; Yee, S.W.; Giacomini, K.M. Pharmacogenetics of antidiabetic drugs. *Adv. Pharmacol.* **2018**, *83*, 361–389. [CrossRef]

112. The Centre for Evidence-Based Medicine. Available online: https://www.cebm.net/ (accessed on 23 February 2024).

113. Heneghan, C.; Aronson, J.K. Sodium valproate: Who knew what and when? Cumulative meta-analysis gives extra insights. *BMJ Evid. Based Med.* **2019**, *24*, 127–129. [CrossRef] [PubMed]

114. Shnayder, N.A.; Grechkina, V.V.; Arkhipov, V.V.; Nasyrova, R.F. Pharmacogenetics-informed pharmacometabolomics as an innovative approach to assessing the safety and risk of pharmacotherapy with valproic acid. *Saf. Risk Pharmacother.* **2023**, *11*, 450–462. [CrossRef]

115. Ji, Y.; Hebbring, S.; Zhu, H.; Jenkins, G.D.; Biernacka, J.; Snyder, K.; Drews, M.; Fiehn, O.; Zeng, Z.; Schaid, D.; et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: Pharmacometabolomics informed pharmacogenomics. *Clin. Pharmacol. Ther.* **2011**, *89*, 97–104. [CrossRef]

116. Ghodke-Puranik, Y.; Thorn, C.F.; Lamba, J.K.; Leeder, J.S.; Song, W.; Birnbaum, A.K.; Altman, R.B.; Klein, T.E. Valproic acid pathway: Pharmacokinetics and pharmacodynamics. *Pharmacogenet. Genom.* **2013**, *23*, 236–241. [CrossRef]

117. Tvarijonaviciute, A.; Martinez-Lozano, N.; Rios, R.; Marcilla de Teruel, M.C.; Garaulet, M.; Cerón, J.J. Saliva as a non-invasive tool for assessment of metabolic and inflammatory biomarkers in children. *Clin. Nutr.* **2020**, *39*, 2471–2478. [CrossRef]

118. de Sá Alves, M.; de Sá Rodrigues, N.; Bandeira, C.M.; Chagas, J.F.S.; Pascoal, M.B.N.; Nepomuceno, G.L.J.T.; da Silva Martinho, H.; Alves, M.G.O.; Mendes, M.A.; Dias, M.; et al. Identification of Possible Salivary Metabolic Biomarkers and Altered Metabolic Pathways in South American Patients Diagnosed with Oral Squamous Cell Carcinoma. *Metabolites* **2021**, *11*, 650. [CrossRef]

119. Brunmair, J.; Gotsmy, M.; Niederstaetter, L.; Neuditschko, B.; Bileck, A.; Slany, A.; Feuerstein, M.L.; Langbauer, C.; Janker, L.; Zanghellini, J.; et al. Finger sweat analysis enables short interval metabolic biomonitoring in humans. *Nat. Commun.* **2021**, *12*, 5993. [CrossRef]

120. Pham, Y.L.; Beauchamp, J. Breath Biomarkers in Diagnostic Applications. *Molecules* **2021**, *26*, 5514. [CrossRef]

121. Trius-Soler, M.; Praticò, G.; Gürdeniz, G.; Garcia-Aloy, M.; Canali, R.; Natella, F.; Brouwer-Brolsma, E.M.; Andrés-Lacueva, C.; Dragsted, L.O. Biomarkers of moderate alcohol intake and alcoholic beverages: A systematic literature review. *Genes Nutr.* **2023**, *18*, 7. [CrossRef]

122. Chachaj, A.; Matkowski, R.; Gröbner, G.; Szuba, A.; Dudka, I. Metabolomics of interstitial fluid, plasma and urine in patients with arterial hypertension: New insights into the underlying mechanisms. *Diagnostics* **2020**, *10*, 936. [CrossRef]

123. Ashurov, Z.S. The evolution of personalized psychiatry. *Pers. Psychiatry Neurol.* **2023**, *3*, 1–2.

124. Bours, M.J.; Drevets, D.A.; McGehee, S.M.; Schilling, B.K. Role of pharmacogenetics in personalized medicine. *Mol. Diagn. Ther.* 2005, 9, 253–261. [Google Scholar] [CrossRef]

125. Green, C.D.; Montgomery, L.; Gessner, D.; Hughes, S. Pharmacogenomics and therapeutic drug monitoring: An essential partnership.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

Pharmacogenomics J. 2003, 3, 299–308. [Google Scholar] [CrossRef]

126. Relling, M.V.; Evans, W.E. Pharmacogenomics in the clinic. *Nature* 2015, 526, 343–350. [Google Scholar] [CrossRef]

127. de Haan, H.; Gaedigk, A.; Frosch, M.; Riedel, A. Challenges in pharmacogenetics and personalized medicine: Drug-drug interactions and ethical considerations. *J. Pers. Med.* 2016, 6, 1–7. [Google Scholar] [CrossRef]

128. Domingues, M.A.; Malavasi, R.C.; Nakano, E.; Rodrigues, L.R.; de Souza, S.C.; de Lima, A.G.; Cortez, L.L.; Fernandes, J.M.; Souza, E.M.; Lopes, L.M.; et al. The role of pharmacogenetic testing in optimizing antidiabetic drug therapies. *Eur. J. Clin. Pharmacol.* 2018, 74, 471–479. [Google Scholar] [CrossRef]

129. Bertino, J.S.; Klein, T.E.; Shuldiner, A.R. Pharmacogenetics in clinical practice: Challenges and opportunities. *Am. J. Health-Syst. Pharm.* 2005, 62, 363–370. [Google Scholar] [CrossRef]

130. McLeod, H.L.; Evans, W.E. Pharmacogenomics: Unlocking the role of individual genetics in drug therapy. *Cancer Chemother. Pharmacol.* 2003, 52, 87–99. [Google Scholar] [CrossRef]

131. Kuehl, P.; Sadee, W. Pharmacogenetics of pharmacokinetics and drug interactions. *Annu. Rev. Pharmacol. Toxicol.* 2005, 45, 87–111. [Google Scholar] [CrossRef]

132. Zhang, L.; Mao, Y.; Liang, J.; He, W.; Zhang, X.; Li, Q. Pharmacogenetics of anticancer drugs: Current status and future directions. *Pharmacogenomics* 2015, 16, 1633–1645. [Google Scholar] [CrossRef]

133. Pirmohamed, M.; Elliott, R.A.; Kesson, C.M.; Watson, W.S.; McHutchison, J.G.; Ferguson, J.; McColl, K.E.; Park, W.; Barritt, A.S. Adverse drug reactions as a cause of hospital admission. *Arch. Intern. Med.* 2004, 164, 1093–1099. [Google Scholar] [CrossRef]

134. Gagne, J.J.; Devarajan, P.; Goldberg, D.S.; Anderson, H.L.; Sinsheimer, J.S.; Mounsey, M.E.; Vasilenko, P.; McGowan, M.; Flory, J.H. A prospective study of pharmacogenetic testing for adverse drug reactions in patients treated with anticancer drugs. *J. Clin. Oncol.* 2019, 37, 1417–1423. [Google Scholar] [CrossRef]

135. Dandara, C.; Lopes, A.; Billaud, J.; Harker, S. Pharmacogenetics: Implications for personalized medicine. *Pharmacogenomics* 2015, 16, 1149–1166. [Google Scholar] [CrossRef]

136. Johnson, J.A.; Ritchie, M.D.; Mansour, H.; Kreutz, R.; Lönnqvist, J.; Rehm, J.; McDonough, M.A.; Brown, S. Clinical pharmacogenetics implementation: A step toward personalized therapy. *Am. J. Med.* 2017, 130, 1327–1334. [Google Scholar] [CrossRef]

137. Moyer, A.; Gach, M.; Menzie, P.; Malis, B.; Munger, R. Genetic influences on drug metabolism and their impact on drug response. *J. Pharm. Sci.* 2010, 99, 2691–2703. [Google Scholar] [CrossRef]

138. Sweeney, M.; Pritchard, M.; Moore, A.; Lim, E.; Gorib, M. Genetic variants in drug metabolizing enzymes and their role in drug response. *Front. Pharmacol.* 2018, 9, 254. [Google Scholar] [CrossRef]

139. Pirmohamed, M.; Williams, S.; Dalen, S.; Lindeboom, S.; Breckenridge, A.M.; O'Reilly, J.; Stouffer, G.; McCabe, A. Genotype-guided dosing of warfarin and adverse drug reactions. *Lancet* 2013, 379, 290–295. [Google Scholar] [CrossRef]

140. Chan, A.T.; Kim, A.; Levin, J.; Wilson, M.D.; Schein, S.; Zang, R.; Simons, J. Pharmacogenomics in personalized medicine: Prospects and challenges. *Genet. Med.* 2014, 16, 457–464. [Google Scholar] [CrossRef] 141. Hughes, T.E.; Lim, S.C.; Wightman, W.; Minassian, A.; Nelson, H.; Charman, S.A. Clinical pharmacogenetics: Impact on drug efficacy and patient safety. *Expert Opin. Pharmacother.* 2018, 19, 1517–1529. [Google Scholar] [CrossRef]

142. Klein, T.E.; Altman, R.B. PharmGKB: The Pharmacogenomics Knowledge Base. *Pharmacogenomics* 2008, 9, 561–566. [Google Scholar] [CrossRef] 143. Veenstra, D.L.; Marshall, M.A.; Sturkenboom, M.; Van Schaik, R.H.; Delleur, L.; van Gils, M.; Stryker, S.; Sirol, N.; de Graaf, E.A. Pharmacogenomic testing and the value of

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(6), 2168-2187 | ISSN:2251-6727

personalized medicine in the treatment of chronic diseases. *JAMA* 2011, 305, 815–821. [Google Scholar] [CrossRef]

144. Lin, J.H.; Wang, P.C.; Hsueh, P.R.; Lee, C.W.; Chen, T.C. Genomic and pharmacogenomic predictors of drug efficacy. *Trends Pharmacol. Sci.* 2015, 36, 308–317. [Google Scholar] [CrossRef]

145. Lee, J.W.; Erez, M.; Chang, Y.; Meyer, M.T.; Park, B.C. Genetic variation and drug response: The future of personalized medicine. *J. Clin. Pharmacol.* 2016, 56, 875–888. [Google Scholar] [CrossRef]

146. Huddart, S.; Cattanach, P.; Goodall, M.; Verma, P.; Schofield, J.; Hoskisson, M. Pharmacogenomics and drug therapy: A guide to personalized medicine. *Br. J. Pharmacol.* 2014, 171, 4189–4200. [Google Scholar] [CrossRef]

147. Lin, M.; Weinstein, J.N.; Sese, B.; Woo, S.; Lee, M. Pharmacogenomics in clinical practice. *J. Med. Genet.* 2009, 46, 749–755. [Google Scholar] [CrossRef]

148. Shuldiner, A.R.; Ritchie, M.D.; Clark, M.P.; Papp, A.C.; Siu, J.; Johnson, S.G. Pharmacogenomic testing in clinical practice: Case study of personalized medicine. *Am. J. Health-Syst. Pharm.* 2009, 66, 137–143. [Google Scholar] [CrossRef]

149. Bi, D.; Brown, M.A.; Jenkins, M.; Gless, S.; Weng, Q.; Zhang, F. The role of pharmacogenetics in cardiovascular diseases: Implications for personalized medicine. *Eur. Heart J.* 2017, 38, 1509–1517. [Google Scholar] [CrossRef]